IN8bio (NASDAQ:INAB) Given New $8.00 Price Target at HC Wainwright

IN8bio (NASDAQ:INAB) had its target price trimmed by HC Wainwright from $12.50 to $8.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

IN8bio Stock Performance

Shares of NASDAQ INAB traded up $0.00 during trading on Wednesday, reaching $0.32. 47,917 shares of the company traded hands, compared to its average volume of 546,124. The stock has a market capitalization of $14.82 million, a PE ratio of -0.42 and a beta of -0.07. The firm has a 50 day simple moving average of $0.30 and a 200-day simple moving average of $0.68. IN8bio has a 52-week low of $0.22 and a 52-week high of $2.48. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp lifted its position in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the period. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.